Seema Singhal

Grants

Grants per year 2003 2003 2005 2006 2007 2010 2021 2022 2027

• 11 Active
• 51 Finished

Grants per year

Search results

• Finished

  Prot# PX-171-003: An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  Proteolix, Inc.

  11/7/07 → 12/31/13

  Project: Research project

• Prot# PX-171-004: An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma

  Singhal, S. (PD/PI)

  Proteolix, Inc.

  11/2/07 → 11/2/10

  Project: Research project

• Prot# KAG-302: Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Comparing Three Doses of Tanespimycin in Patients with Relapsed-Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  PharmaNet, Inc., Kosan Biosciences Incorporated

  11/1/07 → 5/1/13

  Project: Research project

• Research on Adverse Drug Events and Reports: Novel Multiple Myeloma Drugs

  West, D. P. (PD/PI), Belknap, S. M. (Co-PD/PI), Kuzel, T. M. (Co-PD/PI), Kwaan, H. C. (Co-PD/PI), McKoy, J. M. (Co-PD/PI), Mehta, J. (Co-PD/PI), Singhal, S. (Co-PD/PI) & Tallman, M. S. (Co-PD/PI)

  National Cancer Institute

  9/6/07 → 8/31/11

  Project: Research project

• High-Throughput Stem Cell Procurement and Purification for Cell-Based Therapies

  Mehta, J. (PD/PI) & Singhal, S. (Co-PD/PI)

  University of Illinois at Urbana-Champaign, Illinois Department of Public Health

  5/21/07 → 5/20/09

  Project: Research project

• Prot# HuLuc63-1701: Phase 1, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal IgG1 Antibody) in Subjects with Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  PDL BioPharma, Inc.

  3/20/07 → 9/1/11

  Project: Research project

• Prot# XL999-203: A Phase 2 Study of XL999 Administered Intravenously to Subjects with Relapsed/Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  PPD Development, Exelixis Inc.

  8/23/06 → 8/23/09

  Project: Research project

• Prot# NU 06H2: A Multicenter Phase II Study Incorporating DOXIL® and Rituximab into the Magrath Regimen for HIV-Negative and HIV-Positive Patients with Newly Diagnosed Burkitt's and Burkitt-like Lymphoma

  Frankfurt, O. (Co-PD/PI), Gordon, L. I. (Co-PD/PI), Kuzel, T. M. (Co-PD/PI), Mehta, J. (Co-PD/PI), Singhal, S. (Co-PD/PI), Tallman, M. S. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)

  Ortho Biotech Clinical Affairs, LLC

  8/3/06 → 4/1/12

  Project: Research project

• Prot# X05211: A Phase II Trial of Combination Bortezomib and Rituximab as Front-Line Therapy for Low-Grade Non-Hodgkin's Lymphoma (NU Prot# NU 06H1)

  Gordon, L. I. (PD/PI), Frankfurt, O. (Co-PD/PI), Kuzel, T. M. (Co-PD/PI), Mehta, J. (Co-PD/PI), Singhal, S. (Co-PD/PI), Tallman, M. S. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)

  Millennium Pharmaceuticals, Inc.

  6/29/06 → 1/31/20

  Project: Research project

• Prot# Perifosine 212: An Open-Label Phase II Study of the Safety and Efficacy of Perifosine Alone and in Combination with Dexamethasone for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  AOI Pharmaceuticals, Inc.

  5/3/06 → 5/3/11

  Project: Research project

• Prot# 015-00: Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (MK-0683) (L-001079038) in Combination with Bortezomib in Patients With Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  PRA Health Sciences, Merck & Co., Inc.

  4/11/06 → 4/11/09

  Project: Research project

• Prot# 015-00: Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (MK-0683) (L-001079038) in Combination with Bortezomib in Patients With Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  PRA Health Sciences, Merck & Co., Inc.

  4/11/06 → 4/11/09

  Project: Research project

• Prot# PXD101-CLN-5: A Phase IB/II Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Activity Study of PXD101 in Combination with Bortezomib in Patients with Relapsed, Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  Prologue Research International, Inc., CuraGen Corporation

  1/5/06 → 3/1/12

  Project: Research project

• Prot# CC-5013-MM-016: A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects with Multiple Myeloma

  Singhal, S. (PD/PI)

  Prologue Research International, Inc., Celgene Corporation

  10/26/05 → 12/8/11

  Project: Research project

• Nanomaterials for Cancer Diagnostics and Therapeutics

  Mirkin, C. A. (PD/PI), Backman, V. (Co-PD/PI), Dravid, V. P. (Co-PD/PI), Gradishar, W. J. (Co-PD/PI), Kibbe, M. R. (Co-PD/PI), Lee, C. (Co-PD/PI), Meade, T. J. (Co-PD/PI), Nguyen, S. (Co-PD/PI), O'Halloran, T. V. (Co-PD/PI), Odom, T. W. (Co-PD/PI), Paunesku, T. (Co-PD/PI), Rademaker, A. W. (Co-PD/PI), Schatz, G. C. (Co-PD/PI), Scheidt, K. A. (Co-PD/PI), Singhal, S. (Co-PD/PI), Stupp, S. (Co-PD/PI), Tallman, M. S. (Co-PD/PI), Van Duyne, R. P. (Co-PD/PI), Woloschak, G. E. (Co-PD/PI), Woodruff, T. K. (Co-PD/PI) & Zoloth, L. S. (Co-PD/PI)

  National Cancer Institute

  9/30/05 → 8/31/11

  Project: Research project

  • Nanomaterials 100%
  • Cancer Therapeutics 100%
  • Nanotechnology 100%
  • Cancer Diagnostics 100%
  • Cancer Nanotechnology 50%

• CCNE: Project 4/O'Halloran

  O'Halloran, T. V. (PD/PI), Nguyen, S. (Co-PD/PI), Singhal, S. (Co-PD/PI) & Tallman, M. S. (Co-PD/PI)

  National Cancer Institute

  9/30/05 → 8/31/10

  Project: Research project

  • Nanotechnology 100%
  • Cancer Nanotechnology 100%
  • Nanomaterials 50%
  • Cancer Research 33%
  • Extramural Funding 33%

• Prot# B9E-US-X446: A Phase I/II Trial of Combination Bortezomib (VELCADE®) and Gemcitabine Therapy for Patients with Relapsed or Refractory Aggressive B- and T -Cell Non-Hodgkin's Lymphoma (NU Prot# NU 04H4)

  Gordon, L. I. (PD/PI), Gordon, L. I. (Co-PD/PI), Kuzel, T. M. (Co-PD/PI), Mehta, J. (Co-PD/PI), Platanias, L. C. (Co-PD/PI), Singhal, S. (Co-PD/PI), Tallman, M. S. (Co-PD/PI), Williams, S. F. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)

  Eli Lilly and Company

  9/12/05 → 10/31/17

  Project: Research project

• Prot# VEL-03-082: A Phase I/II Trial of Combination Bortezomib (VELCADE®) and Gemcitabine Therapy for Patients with Relapsed or Refractory Aggressive B- and T -Cell Non-Hodgkin's Lymphoma (NU Prot# NU 04H4)

  Gordon, L. I. (PD/PI), Gordon, L. I. (Co-PD/PI), Kuzel, T. M. (Co-PD/PI), Mehta, J. (Co-PD/PI), Platanias, L. C. (Co-PD/PI), Singhal, S. (Co-PD/PI), Tallman, M. S. (Co-PD/PI), Williams, S. F. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)

  Millennium Pharmaceuticals, Inc.

  7/8/05 → 10/31/14

  Project: Research project

• Prot# PXD101-301-G: A Phase II Clinical Trial of PXD101 In Patients with Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  Prologue Research International, Inc., CuraGen Corporation

  5/2/05 → 12/1/11

  Project: Research project

• Prot# NU 03Z2: Prospective Fertility Assessment for Men and Women Receiving 90Yttrium-Zevalin Therapy

  Brannigan, R. E. (Co-PD/PI), Singhal, S. (Co-PD/PI), Spies, S. M. (Co-PD/PI), Tallman, M. S. (Co-PD/PI), Williams, S. F. (Co-PD/PI), Winter, J. N. (Co-PD/PI) & Woodruff, T. K. (Co-PD/PI)

  Biogen Inc.

  5/24/04 → 6/26/07

  Project: Research project

• Prot# NU 03Z2: Prospective Fertility Assessment for Men and Women Receiving 90Yttrium-Zevalin Therapy

  Brannigan, R. E. (Co-PD/PI), Singhal, S. (Co-PD/PI), Spies, S. M. (Co-PD/PI), Tallman, M. S. (Co-PD/PI), Williams, S. F. (Co-PD/PI), Winter, J. N. (Co-PD/PI) & Woodruff, T. K. (Co-PD/PI)

  Biogen Inc.

  5/24/04 → 6/26/07

  Project: Research project

• Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL) Combining 90-Yttrium-Zevalin® and the Redox-Modulating Agent, Motexafin Gadolinium (MGd) (Prot# 106-P115)

  Gordon, L. I. (Co-PD/PI), Kuzel, T. M. (Co-PD/PI), Singhal, S. (Co-PD/PI), Spies, S. M. (Co-PD/PI), Tallman, M. S. (Co-PD/PI), Williams, S. F. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)

  Biogen Inc.

  9/5/03 → 1/1/11

  Project: Research project

• Prot# CC-5013-MM-014: A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single Agent CC-5013 in Subjects with Relapsed and Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  Celgene Corporation

  9/2/03 → 12/30/05

  Project: Research project

• Prot# CC-5013-MM-014: A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single Agent CC-5013 in Subjects with Relapsed and Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  Celgene Corporation

  9/2/03 → 12/30/05

  Project: Research project

• Prot# NU 02H8 (PCYC-0213): A Phase I/II Trial of Redox Regulation in Patients with Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90Yttrium-Zevalin & Redox-Modulating Agent, Motexafin Gadolinium (MGd)

  Gordon, L. I. (Co-PD/PI), Kuzel, T. M. (Co-PD/PI), Singhal, S. (Co-PD/PI), Spies, S. M. (Co-PD/PI), Tallman, M. S. (Co-PD/PI), Williams, S. F. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)

  Pharmacyclics, Inc.

  7/23/03 → 9/1/11

  Project: Research project